The Commission has established the Sepsis Program Oversight Group (Oversight Group) to provide strategic advice and guidance to inform program and project implementation. Members include people with lived experience of sepsis, as well as adult and paediatric clinical experts from around Australia.
These Frequently Asked Questions provides answers to commonly asked questions about the web tool's purpose, features, update frequency, development, data sources, consumer enquiry pathways and the role of the Commission.
This decision aid can be used with your doctor to help you decide whether to use antibiotics when you have a flare-up (exacerbation) of your chronic obstructive pulmonary disease (COPD).
This decision aid can be used with your doctor to help you decide whether to use antibiotics when you or your child has sinusitis (acute rhinosinusitis).
This issue includes items on prevention, oral health, medication safety, patient engagement, COVID-19, and more. Also covered are the latest from Australian Prescriber, BMJ Quality & Safety, Pediatric Quality & Safety, Public Health Research & Practice and International Journal for Quality in Health Care.
This resource accompanies the Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard. It describes what the quality statements mean for healthcare services and provides indicators to support local quality improvement activity.
This resource lists the eight quality statements in the clinical care standard that aim to ensure the safe and appropriate use of psychotropic medicines in people with cognitive disability or impairment.
The Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard contains eight quality statements and seven indicators to ensure the safe and appropriate use of psychotropic medicines in people with cognitive disability or impairment and uphold their rights, dignity, health and quality of life.
